Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing

Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of vario...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pharmacology and experimental therapeutics Vol. 370; no. 3; pp. 408 - 415
Main Authors Nakano, Masataka, Fukami, Tatsuki, Nakajima, Miki
Format Journal Article
LanguageEnglish
Published United States 01.09.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of various drug-metabolizing enzymes. CAR mRNA and protein levels in human hepatocellular carcinoma-derived HepG2 cells were increased by knockdown of ADAR1 and slightly increased by ADAR2, indicating that ADARs negatively regulate CAR expression. Increased luciferase activity of a reporter plasmid containing the CYP3A4 promoter region by phenobarbital was augmented by transfection of siRNA for ADAR1 (siADAR1) but not by siADAR2. In addition, the knockdown of ADAR1 resulted in the enhanced induction of CYP2B6 and CYP3A4 mRNA by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde -(3,4-dichlorobenzyl)oxime and phenobarbital, respectively. These results suggest that ADAR1-mediated downregulation of CAR affects its downstream cytochrome P450 expression. When the transcription was inhibited by -amanitin, the degradation of CAR mRNA was attenuated by knockdown of ADAR1, suggesting that the increase in CAR mRNA level by ADAR1 knockdown is a post-transcriptional event. Finally, we found that ADAR1 knockdown promotes the splicing of CAR as a mechanism of the increased expression of CAR by ADAR1 knockdown. In conclusion, this study revealed that ADAR1 plays a role in modulating xenobiotic metabolism potency via regulation of CAR. SIGNIFICANCE STATEMENT: This study revealed that adenosine deaminase acting on RNA 1 (ADAR1) and ADAR2, which catalyze adenosine-to-inosine RNA editing, downregulate the expression of constitutive androstane receptor (CAR) in human liver-derived cells by attenuating splicing. The downregulation of CAR by ADARs affected its downstream cytochrome P450 expression. ADARs would play a role in modulating xenobiotic metabolism potency via regulation of CAR.
AbstractList Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of various drug-metabolizing enzymes. CAR mRNA and protein levels in human hepatocellular carcinoma-derived HepG2 cells were increased by knockdown of ADAR1 and slightly increased by ADAR2, indicating that ADARs negatively regulate CAR expression. Increased luciferase activity of a reporter plasmid containing the CYP3A4 promoter region by phenobarbital was augmented by transfection of siRNA for ADAR1 (siADAR1) but not by siADAR2. In addition, the knockdown of ADAR1 resulted in the enhanced induction of CYP2B6 and CYP3A4 mRNA by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde -(3,4-dichlorobenzyl)oxime and phenobarbital, respectively. These results suggest that ADAR1-mediated downregulation of CAR affects its downstream cytochrome P450 expression. When the transcription was inhibited by -amanitin, the degradation of CAR mRNA was attenuated by knockdown of ADAR1, suggesting that the increase in CAR mRNA level by ADAR1 knockdown is a post-transcriptional event. Finally, we found that ADAR1 knockdown promotes the splicing of CAR as a mechanism of the increased expression of CAR by ADAR1 knockdown. In conclusion, this study revealed that ADAR1 plays a role in modulating xenobiotic metabolism potency via regulation of CAR. SIGNIFICANCE STATEMENT: This study revealed that adenosine deaminase acting on RNA 1 (ADAR1) and ADAR2, which catalyze adenosine-to-inosine RNA editing, downregulate the expression of constitutive androstane receptor (CAR) in human liver-derived cells by attenuating splicing. The downregulation of CAR by ADARs affected its downstream cytochrome P450 expression. ADARs would play a role in modulating xenobiotic metabolism potency via regulation of CAR.
Author Nakano, Masataka
Nakajima, Miki
Fukami, Tatsuki
Author_xml – sequence: 1
  givenname: Masataka
  surname: Nakano
  fullname: Nakano, Masataka
  organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan
– sequence: 2
  givenname: Tatsuki
  surname: Fukami
  fullname: Fukami, Tatsuki
  organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan
– sequence: 3
  givenname: Miki
  surname: Nakajima
  fullname: Nakajima, Miki
  email: nmiki@p.kanazawa-u.ac.jp
  organization: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan nmiki@p.kanazawa-u.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31270214$$D View this record in MEDLINE/PubMed
BookMark eNo9kMtOwzAQRS1URB-wZof8A2n9yENeRm2hSBVIBdaR40yKq9SJbAfot_CzuC2wmivNvXdGZ4wGpjWA0C0lU0pZPNt14IMSU5YSSsQFGtGE0ShoPkAjQhiLeJImQzR2bkcIjeOUX6EhpywjjMYj9J1XYFqnDeAFyL020oHDufLabHFr8OYpx4v201jY9o30gP074OVXZ8E5HfZtjeetcV773usPwLmpbOu8DH0bUND51mJtTqlVv5cGr4PLRguwYVZ4Dk3jcHnAufdgenk6-9I1WgVxjS5r2Ti4-Z0T9Ha_fJ2vovXzw-M8X0cqJrGP6jpjLEniKoMqS1NOVckVVLJOFS9VJlMuIJNxSUXFQYAUtUgSUgIIRViSUT5Bs3OvCq87C3XRWb2X9lBQUhwxF0fMQYnijDkk7s6Jri_3UP37_7jyHyaRfpw
CitedBy_id crossref_primary_10_1124_dmd_121_000390
crossref_primary_10_3390_cells9112395
crossref_primary_10_1016_j_bcp_2019_113697
crossref_primary_10_1124_dmd_123_001396
crossref_primary_10_1021_acsami_2c19285
crossref_primary_10_1016_j_dmpk_2020_11_002
Cites_doi 10.1016/S0928-0987(00)00112-3
10.1016/j.bcp.2010.02.023
10.1073/pnas.91.24.11457
10.1016/j.febslet.2007.11.011
10.1002/hep.21671
10.1074/jbc.M709382200
10.1124/mol.54.6.1113
10.1016/j.pharmthera.2017.07.003
10.1074/jbc.M109.016808
10.1080/03602530600569828
10.1016/j.jhep.2010.10.029
10.1124/pr.58.4.6
10.1038/nrm.2015.4
10.1124/dmd.119.086702
10.1002/bies.201700188
10.1038/nbt.2122
10.1093/nar/gkw767
10.1073/pnas.0909731106
10.1136/gut.2006.093260
10.4161/rna.7.2.11568
10.1016/j.tibs.2008.06.001
10.1074/jbc.TM118.004166
10.1097/00008571-200007000-00001
10.1158/0008-5472.CAN-04-0166
10.1016/j.apsb.2016.07.016
10.1074/jbc.M115.699363
10.1080/15476286.2016.1203501
10.1038/nsmb.3403
10.1186/gm508
10.2133/dmpk.19.103
10.1074/jbc.M310068200
10.1210/me.2002-0244
10.1074/jbc.RA117.001197
10.1006/abbi.2001.2499
10.1074/jbc.M600931200
ContentType Journal Article
Copyright Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
Copyright_xml – notice: Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1124/jpet.119.260109
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0103
EndPage 415
ExternalDocumentID 10_1124_jpet_119_260109
31270214
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
2WC
3O-
4.4
53G
5GY
5RE
5VS
8WZ
A6W
AAJMC
AAYOK
ABCQX
ABIVO
ABJNI
ABOCM
ABSQV
ACGFO
ACGFS
ACNCT
ADBBV
ADCOW
ADIYS
AENEX
AERNN
AFFNX
AFHIN
AFOSN
AGFXO
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
HZ~
INIJC
KQ8
L7B
LSO
MJL
MVM
NPM
O9-
OHT
OK1
P2P
R.V
R0Z
RHF
RHI
RPT
TR2
UQL
VH1
W2D
W8F
WH7
WOQ
X7M
YBU
YHG
YQT
ZGI
ZXP
AAYXX
CITATION
ID FETCH-LOGICAL-c404t-ff722554d7ed76631cb3cedaf6c3bc7a639e7a4b19d3e9ea9f9550bee9c025713
ISSN 0022-3565
IngestDate Thu Sep 26 19:43:31 EDT 2024
Sat Sep 28 08:32:24 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c404t-ff722554d7ed76631cb3cedaf6c3bc7a639e7a4b19d3e9ea9f9550bee9c025713
OpenAccessLink https://jpet.aspetjournals.org/content/jpet/370/3/408.full.pdf
PMID 31270214
PageCount 8
ParticipantIDs crossref_primary_10_1124_jpet_119_260109
pubmed_primary_31270214
PublicationCentury 2000
PublicationDate 2019-09-01
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: 2019-09-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of pharmacology and experimental therapeutics
PublicationTitleAlternate J Pharmacol Exp Ther
PublicationYear 2019
References 2019081415070058000_370.3.408.19
2019081415070058000_370.3.408.18
2019081415070058000_370.3.408.14
2019081415070058000_370.3.408.36
2019081415070058000_370.3.408.17
2019081415070058000_370.3.408.16
Gerber (2019081415070058000_370.3.408.9) 1997; 3
2019081415070058000_370.3.408.22
2019081415070058000_370.3.408.21
2019081415070058000_370.3.408.24
2019081415070058000_370.3.408.23
Nakano (2019081415070058000_370.3.408.15) 2018; 181
2019081415070058000_370.3.408.20
Hedrich (2019081415070058000_370.3.408.10) 2016; 6
2019081415070058000_370.3.408.29
2019081415070058000_370.3.408.26
2019081415070058000_370.3.408.25
2019081415070058000_370.3.408.28
2019081415070058000_370.3.408.27
2019081415070058000_370.3.408.1
2019081415070058000_370.3.408.3
2019081415070058000_370.3.408.4
2019081415070058000_370.3.408.11
2019081415070058000_370.3.408.33
2019081415070058000_370.3.408.32
2019081415070058000_370.3.408.13
2019081415070058000_370.3.408.35
2019081415070058000_370.3.408.12
2019081415070058000_370.3.408.34
Ben-Shoshan (2019081415070058000_370.3.408.2) 2017; 14
2019081415070058000_370.3.408.5
2019081415070058000_370.3.408.6
2019081415070058000_370.3.408.7
2019081415070058000_370.3.408.31
2019081415070058000_370.3.408.8
2019081415070058000_370.3.408.30
References_xml – ident: 2019081415070058000_370.3.408.16
  doi: 10.1016/S0928-0987(00)00112-3
– ident: 2019081415070058000_370.3.408.25
  doi: 10.1016/j.bcp.2010.02.023
– ident: 2019081415070058000_370.3.408.11
  doi: 10.1073/pnas.91.24.11457
– ident: 2019081415070058000_370.3.408.35
  doi: 10.1016/j.febslet.2007.11.011
– ident: 2019081415070058000_370.3.408.21
  doi: 10.1002/hep.21671
– ident: 2019081415070058000_370.3.408.32
  doi: 10.1074/jbc.M709382200
– ident: 2019081415070058000_370.3.408.29
  doi: 10.1124/mol.54.6.1113
– volume: 181
  start-page: 13
  year: 2018
  ident: 2019081415070058000_370.3.408.15
  article-title: Significance of A-to-I RNA editing of transcripts modulating pharmacokinetics and pharmacodynamics
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2017.07.003
  contributor:
    fullname: Nakano
– ident: 2019081415070058000_370.3.408.8
  doi: 10.1074/jbc.M109.016808
– ident: 2019081415070058000_370.3.408.3
  doi: 10.1080/03602530600569828
– ident: 2019081415070058000_370.3.408.28
  doi: 10.1016/j.jhep.2010.10.029
– ident: 2019081415070058000_370.3.408.13
  doi: 10.1124/pr.58.4.6
– ident: 2019081415070058000_370.3.408.17
  doi: 10.1038/nrm.2015.4
– ident: 2019081415070058000_370.3.408.18
  doi: 10.1124/dmd.119.086702
– ident: 2019081415070058000_370.3.408.34
  doi: 10.1002/bies.201700188
– ident: 2019081415070058000_370.3.408.22
  doi: 10.1038/nbt.2122
– ident: 2019081415070058000_370.3.408.23
  doi: 10.1093/nar/gkw767
– ident: 2019081415070058000_370.3.408.7
  doi: 10.1073/pnas.0909731106
– ident: 2019081415070058000_370.3.408.36
  doi: 10.1136/gut.2006.093260
– ident: 2019081415070058000_370.3.408.1
  doi: 10.4161/rna.7.2.11568
– ident: 2019081415070058000_370.3.408.12
  doi: 10.1016/j.tibs.2008.06.001
– volume: 3
  start-page: 453
  year: 1997
  ident: 2019081415070058000_370.3.408.9
  article-title: Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette
  publication-title: RNA
  contributor:
    fullname: Gerber
– ident: 2019081415070058000_370.3.408.27
  doi: 10.1074/jbc.TM118.004166
– ident: 2019081415070058000_370.3.408.19
  doi: 10.1097/00008571-200007000-00001
– ident: 2019081415070058000_370.3.408.33
  doi: 10.1158/0008-5472.CAN-04-0166
– volume: 6
  start-page: 413
  year: 2016
  ident: 2019081415070058000_370.3.408.10
  article-title: Insights into CYP2B6-mediated drug-drug interactions
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2016.07.016
  contributor:
    fullname: Hedrich
– ident: 2019081415070058000_370.3.408.14
  doi: 10.1074/jbc.M115.699363
– volume: 14
  start-page: 587
  year: 2017
  ident: 2019081415070058000_370.3.408.2
  article-title: ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis
  publication-title: RNA Biol
  doi: 10.1080/15476286.2016.1203501
  contributor:
    fullname: Ben-Shoshan
– ident: 2019081415070058000_370.3.408.26
  doi: 10.1038/nsmb.3403
– ident: 2019081415070058000_370.3.408.30
  doi: 10.1186/gm508
– ident: 2019081415070058000_370.3.408.31
  doi: 10.2133/dmpk.19.103
– ident: 2019081415070058000_370.3.408.5
  doi: 10.1074/jbc.M310068200
– ident: 2019081415070058000_370.3.408.20
  doi: 10.1210/me.2002-0244
– ident: 2019081415070058000_370.3.408.4
  doi: 10.1074/jbc.RA117.001197
– ident: 2019081415070058000_370.3.408.24
  doi: 10.1006/abbi.2001.2499
– ident: 2019081415070058000_370.3.408.6
  doi: 10.1074/jbc.M600931200
SSID ssj0014463
Score 2.3820572
Snippet Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study,...
SourceID crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 408
SubjectTerms Adenosine Deaminase - deficiency
Adenosine Deaminase - genetics
Adenosine Deaminase - metabolism
Biocatalysis
Cytochrome P-450 CYP2B6 - biosynthesis
Cytochrome P-450 CYP3A - biosynthesis
Down-Regulation
Enzyme Induction
Gene Knockdown Techniques
Hep G2 Cells
Humans
Liver - cytology
Receptors, Cytoplasmic and Nuclear - genetics
RNA Splicing
RNA Stability
RNA-Binding Proteins - genetics
RNA-Binding Proteins - metabolism
Title Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing
URI https://www.ncbi.nlm.nih.gov/pubmed/31270214
Volume 370
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXKkNBeEONrA4buA5qQuowldpPmMdoGE4JqQp3Ut8pxHKnrllYkBcZf4T_wG3evnQ93GhLwEqVOnCg9R_axfXwvY29QcWAvKQIv1IOhR_FKPJmq0FNBzv1MCBwIGYPsKDw9Fx8ng0mv99txLa2q9ED9vHNfyf-gimWIK-2S_Qdk24diAZ4jvnhEhPH4VxgnGYX6Jp14rCV5Wkpd9hNlncxF_8soQYH8HSubfPPaiMyTH7X11ehEytdpzAJkICJz44LUIuVyILuL8aqbWnau_xOZOLxj_LRvZmL48rIk-ZpUKLwpZDgF96b18KY7vOio6AjfZRct2wZ_Wssy4GwIa-X-SM6lSRHe_yxLWeGvlnarOX64IZ2sytV85la5mF1JuzWgLq9nN_zOvoWdU90iBzTfccjdJpvbZCM1N7nTAAsTJeKOjiEQ1DHgSATP4wMKpGbCMlQOTZZXhiecFuMDu7X1Vizu5tI9dj_Aho1a1A-T1lJEQ2teh4_C97279bZN9qCpvyaC1oYzRtaMH7GHNSyQWHJtsZ4uHrO9MwvR9T6MHTj2YQ_OHPCesF8tA6FjIFgGwqIAZCC4DAREFzoGwiIHl4HQMRAaBsKsMLUMA2GNgWAYCOk1OAyEhoFP2fn7k_HRqVen-_CUOBSVl-cRdi4DkUU6i1AI-yrlSmcyDxVPVSRRS-tIitSPM65jLeM8xuF1qnWsULhHPn_GNopFobcZDIXCm1Qm4kwhJtEww5aI1oBDzeUw4DvsbfP_T5c2qsvUjIYDMSXU8CyeWtR22HOLT3tjA-KLP155yTY7Lr9iG9XXld5F7Vqlrw1hbgBh5aHC
link.rule.ids 315,783,787,27936,27937
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adenosine+Deaminases+Acting+on+RNA+Downregulate+the+Expression+of+Constitutive+Androstane+Receptor+in+the+Human+Liver-Derived+Cells+by+Attenuating+Splicing&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Nakano%2C+Masataka&rft.au=Fukami%2C+Tatsuki&rft.au=Nakajima%2C+Miki&rft.date=2019-09-01&rft.eissn=1521-0103&rft.volume=370&rft.issue=3&rft.spage=408&rft_id=info:doi/10.1124%2Fjpet.119.260109&rft_id=info%3Apmid%2F31270214&rft.externalDocID=31270214
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon